GSPT1 and acute myeloid leukemia: The first-in-class GSPT1 degrader CC-885 demonstrated cytotoxicity across multiple cell lines derived from different tumor types, as well as efficacy against primary samples from patients with acute myeloid leukemia (AML) with relative sparing of lymphocytes.